Gene test could prevent risky drug interactions in HIV patients

NCT ID NCT05789173

Recruiting now Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a person's genetic makeup and the HIV drug efavirenz change the way the body processes methadone and tizanidine. Sixty healthy volunteers will be grouped by their CYP2B6 gene type and take these drugs with and without efavirenz. The goal is to understand why some people may get too much or too little drug effect, which could lead to safer dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methadone, Tizanidine, Efavirenz
What this could lead to: If successful, this could help doctors predict and avoid dangerous drug interactions in people taking efavirenz with methadone or tizanidine.
What could go wrong: This is an early-phase study in 60 healthy volunteers, not patients. Results may not apply to real-world clinical settings or people with HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-DRUG INTERACTION

Contacts and locations

Locations

Indiana University School of Medicine
RECRUITING

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.